Document text
Centers for Disease Control and Prevention
National Center for Immunization and Respiratory Di seases
Photographs and images included in this presentation a re licensed solely for CDC/NCIRD online and present ation
use. No rights are implied or extended for use in pr inting or any use by other CDC CIOs or any external audiences.
Adult Respiratory Syncytial Virus (RSV) Session
Camille Kotton, MD Chair, Adult RSV Work Group
Advisory Committee on Immunization Practices (ACIP)October 25, 2023
RSVPreF3 (Arexvy, GSK) is a 1-dose adjuvanted (AS01 E)
recombinant prefusion F protein (preF) vaccine.
RSVpreF (Abrysvo, Pfizer) is a 1-dose recombinant preF vacci ne. In June 2023, CDC’s Advisory Committee on Immunizat ion
Practices (ACIP) voted to recommend that adults age s 60
years and older may receive a single dose of RSV va ccine
using shared clinical decision making.
https://www.cdc.gov/mmwr/volumes/72/wr/mm7229a4.htm2
The Work Group reviewed CDC vaccine safety surveill ance plans for RSV vaccination in
adults ≥60 years.
GSK shared with the Work Group results of an immuno -bridging study showing non-
inferior humoral immune responses to RSV vaccinatio n in immunocompetent adults
50–59, compared with immunocompetent adults ≥60 (in whom efficacy was
demonstrated).
The Work Group discussed the potential role of RSV vaccination in adults younger than
60 years, including subpopulations that would benef it most from vaccination and
equity implications. Issues under discussion since the June meeting
3
The Work Group reviewed CDC vaccine safety surveillan ce plans for RSV
vaccination in adults ≥60 years.
–V-safe ( https://vsafe.cdc.gov ) has launched for older adult RSV vaccination
–Today’s session will not include RSV vaccine uptake data or safety surveillance data;
data are premature this early into the vaccination program
–Uptake and safety results will be shared at a futur e ACIP meeting Issues under discussion since the June meeting
4
Agenda: Wednesday October 25, 2023
RSVPreF3 safety and immunogenicity in adults aged 50–59 years, compared with adults aged ≥60 years
Epidemiology of RSV hospitalization in adults, with a
focus on adults aged 50–59 years
Work Group considerations regarding RSV vaccination in adults aged 50–59 years Dr. Susan Gerber (GSK) Dr. Monica Patton (CDC) Dr. Amadea Britton (CDC)
5
Adult RSV Work Group Membership
6ACIP Voting Members
Camille Kotton (Chair) Keipp Talbot Sarah Long Ex Officio Members
Rachel Zhang (FDA) Judy Beeler (FDA) Nicholas Geagan (FDA) Nadine Peart Akindele (FDA) Sonnie Kim (NIH/NIAID) Jeffrey Kelman (CMS) Michelle Juaneza (HRSA/VICP)Uzo Chukwuma (IHS) Valerie Marshal (OIDP) Consultants
Robert Atmar (Baylor Coll. of Medicine) Helen Chu (U Washington) Peter Donofrio (Vanderbilt University) Marie Griffin (Vanderbilt University) Cynthia Lucero-Obusan (VHA) Tracy Ruckwardt (NIH/NIAID) Jonathan Temte (U Wisconsin) Rebecca Morgan (Case Western) Doug Campos-Outcalt (U Arizona)
Liaisons
Kenneth Schmader (AGS) Vidya Sundareshan (ACP) Gretchen LaSalle (AAFP) April Killikelly (NACI/PHAC) Winnie Su (NACI/PHAC) Katherine Williams (APTR) Ruth Lynfield (NFID) Bindy Crouch (AIM) Steven Pergam (IDSA) Elizabeth Skoy (APhA)
CDC Contributors
Amadea Britton (co-lead) Michael Melgar (co-lead) Lauren Roper Fiona Havers Chris Taylor Monica Patton Meredith McMorrow Diya Surie Jennifer DeCuir Mila Prill Monica Godfrey Ruth Link-Gelles Amanda Payne Danielle Moulia Megan Wallace Natalie Thornburg Melissa Coughlin Jefferson Jones Katherine Fleming-Dutra Ismael Ortega Sanchez Noelle Molinari Pragna Patel Aron Hall Hannah Rosenblum Derrell Powers Raigan Wheeler Jarrett Gartin Elizabeth Greene Manisha Patel Lisa Grohskopf Anne Hause David Shay Christine Olson Tom Shimabukuro Karen Broder Neil Murthy Patricia Wodi Andrew Leidner Jamison Pike Sarah Meyer Nicole Dowling
7
For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov
The findings and conclusions in this report are tho se of the authors and do not necessarily represent the official
position of the Centers for Disease Control and Pre vention.
Photographs and images included in this presentatio n are licensed solely for CDC/NCIRD online and pres entation
use. No rights are implied or extended for use in p rinting or any use by other CDC CIOs or any externa l audiences.